ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1384

Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus

Amanda Marsden1, Georgina Tiller2, Angelyne Rivera3, Maitri Deep Rai3, Lori Tucker3, Jaime Guzman4, Kimberly Morishita2, Kristin Houghton2, Shreya Moodley3 and David Cabral5, 1BC Children's Hospital, Castle Hill, Australia, 2University of British Columbia - Vancouver, Vancouver, BC, Canada, 3British Columbia Children's Hospital, Vancouver, BC, Canada, 4University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, 5BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada

Meeting: ACR Convergence 2022

Keywords: Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Childhood onset SLE is an autoantibody mediated, multisystem disease which can include cardiac manifestations. Because cardiac involvement can develop insidiously, an earlier review from our center suggested that routine echocardiogram (ECHO) screening could allow earlier recognition. We therefore implemented a quality improvement initiative with routine ECHO screening following diagnosis and then two yearly, or as indicated if abnormalities were identified. The aim of this study is to determine the frequency and type of abnormal ECHO findings identified when testing performed as routine screening or for clinical indication in children with SLE followed at BC Children’s Hospital and to determine the association with disease activity.

Methods: All children (< 18 years) diagnosed with SLE from 2005 to 2015 were identified from our records (cutaneous or drug induced lupus were excluded). By chart review we collected all ECHO and EKG results and clinical data both at diagnosis and at time of ECHO testing including SLEDAI score and ESR as disease activity measures.

Results: 81 children with SLE were identified. At diagnosis, mean age was 13.4y; mean SLEDAI score was 13.2 (range 1-45), and mean ESR 56.3 (range 10-136); 98% (79/81) had at least one ECHO. The median interval from diagnosis to first ECHO was 1.5m (range 0-32); the mean associated SLEDAI score was 9 (range 0-32) and ESR 42.3 (range 3-136). Initial ECHO was requested routinely in 82% (65/79) and for clinical indication in 18% (14/79). Of the 23% (18/79) with abnormalities, mean SLEDAI was 14.3 (range 1-32) and ESR 68 (range 7-136). Of the 77% (61/79) with no abnormalities, mean SLEDAI was 7.3 (range 0-32) and ESR 34.6 (range 3-122). ECHO abnormalities were found in 11% (7/65) of patients routinely tested with no clinical indications and in 79% (11/14) with clinical indication. Abnormalities identified are shown in the table and include pericardial effusion, thickened left ventricular wall likely SLE related and PFO and PDA, likely congenital.

62% (50/81) had at least two echocardiograms with median time interval from diagnosis to second ECHO 24.7m (range 0.3-71.7m). The mean SLEDAI at second ECHO was 4.9 (range 0-32), ESR was 20.4 (range 4-132). The mean SLEDAI score of the 12 patients with an abnormal second ECHO was 7 with ESR 26.2. 6/12 (50%) did not have abnormalities on initial ECHO; one of these was performed for clinical indication and showed a new abnormality. 2/12 had previous abnormality and were noted to have progressive worsening.

Conclusion: Among children diagnosed with SLE, 23% were identified by ECHO with cardiac abnormalities; of these 61% had a cardiac clinical indication for testing and 39% were tested as a ‘routine’ practice. The frequency of ECHO abnormalities suggest testing soon after diagnosis may identify SLE and non-SLE abnormalities for comparison against future tests done routinely, or for clinical indication and to determine evolution of changes. SLEDAI score and ESR were not predictive of positive echocardiographic findings, though did tend to be higher than the entire group. This review may inform the utility and optimal practice of echocardiographic screening in pediatric SLE.

Supporting image 1


Disclosures: A. Marsden, None; G. Tiller, None; A. Rivera, None; M. Rai, None; L. Tucker, None; J. Guzman, None; K. Morishita, None; K. Houghton, None; S. Moodley, None; D. Cabral, None.

To cite this abstract in AMA style:

Marsden A, Tiller G, Rivera A, Rai M, Tucker L, Guzman J, Morishita K, Houghton K, Moodley S, Cabral D. Echocardiographic Screening in Childhood Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/echocardiographic-screening-in-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/echocardiographic-screening-in-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology